Product
RNA MCTI CIMATEC HDT
1 clinical trial
2 indications
Indication
COVID-19Indication
COVID-19 vaccineClinical trial
Phase IIb, Randomized, Double-blind, Non-inferior, Multicenter Study to Evaluate the Safety and Immunogenicity of the Self-replicating Nanoparticle Carrier Replicon RNA Carrier (repRNA) Vaccine in Adults 18 to 65 Years of AgeStatus: Not yet recruiting, Estimated PCD: 2023-03-01